A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results C. MilaneseE. Beghiand the MS Centers of Lombardia Region OriginalPaper Pages: s171 - s173
Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience C. PozzilliL. ProsperiniV. Tomassini OriginalPaper Pages: s174 - s178
The IFNβ treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy M. TrojanoD. PaolicelliP. Livrea OriginalPaper Pages: s179 - s182
Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study A. Ghezzion behalf of the Immunomodulatory Treatment of Early onset MS (ITEMS) Group OriginalPaper Pages: s183 - s186
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis E. CapelloR. Saccardiand the Italian GITMO-Neuro Intergroup on ASCT for Multiple Sclerosis OriginalPaper Pages: s200 - s203
Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging M. RovarisM. Filippi OriginalPaper Pages: s204 - s208
Multiple sclerosis patients and immunomodulation therapies: the potential role of new MRI techniques to assess responders versus non-responders G. TedeschiA. Gallo OriginalPaper Pages: s209 - s212
Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments S. MalucchiM. CapobiancoA. Bertolotto OriginalPaper Pages: s213 - s214
Immunological markers in multiple sclerosis: tackling the missing elements L. RinaldiP. Gallo OriginalPaper Pages: s215 - s217
